Transient mRNA T-Cell Therapy for HBV-Related Liver Cancer (HCC)

Targeting HBV-Related Liver Cancer

• 💡 Hepatitis B Virus (HBV) infection can lead to chronic conditions and, in a small proportion of cases, to Hepatocellular Carcinoma (HCC), the most severe outcome.
• 🔬 In chronically infected individuals, the adaptive immune response against HBV breaks down, making it a target for T-cell therapy to reconstitute immunity.
• 📌 HBV antigens are present in HCC cells due to viral integration into the host genome, making them a viable tumor antigen target for therapy.

mRNA T-Cell Engineering Approach

• 🚀 The therapy uses mRNA electroporation to engineer T-cells, a method distinct from permanent viral vector transduction.
• ✅ This approach results in transient expression of HBV-specific T-cell receptors (lasting 3-5 days), offering a safer, "hit-and-run" effect.
• 📈 The transient nature allows for a dose escalation infusion strategy, starting with low quantities and gradually increasing, minimizing adverse events.

Clinical Efficacy and Immune Response

• 📊 Despite the short-lived function, clinical data showed tumor regression in patients with HBV-related HCC, even occurring months after the last T-cell infusion.
• 🔬 Infusion of mRNA T-cells was associated with immune alterations, including liver inflammation and spikes in chemokines like CXCL9 and CXCL10, indicating immune system activation.
• 🔑 Evidence suggests epitope spreading, where the therapy induced T-cells specific not only to the targeted HBV envelope antigen but also to other HBV antigens like core and polymerase.

Mechanism and Future Directions

• 🧠 The hypothesis is that transient T-cell infusions alter the tumor microenvironment, leading to the induction or recruitment of more robust, tumor-specific T-cells.
• 🚫 This transient approach aims to avoid T-cell exhaustion often seen with persistently active T-cell therapies.
• 🌱 Future strategies include combining mRNA T-cell therapy with immunomodulators like checkpoint inhibitors to further boost the immune response and treat chronic HBV infection.